Invega Oral Tablet, Extended Release 1.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Invega: Oral tablet, extended release (1.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_14552.JPG
Invega 1.5mg ER Tab
Janssen Pharmaceuticals, Inc, fomerly Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals
Pill Identification: PAL 1.5,PALI 1.5 

What is this Medicine?

PALIPERIDONE (pal ee PER i done) is used to treat schizophrenia and schizoaffective disorder.

CVS Pharmacy Patient Statistics for Invega: Oral tablet, extended release(1.5mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Invega 1.5mg Extended-Release Tablet

NDC: 504580554
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Schizophrenia, Schizoaffective Disorder

Sometimes used for but not FDA approved for the following conditions:
Mania, Bipolar Disorder, Agitation

Storage Information
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Invega 1.5mg Extended-Release Tablet
Drug Image file DrugItem_14552.JPG
Janssen Pharmaceuticals, Inc, fomerly Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals
Pill Identification: PAL 1.5,PALI 1.5 
Shape: oblong
Color: orange-brown

Reported Side Effects for Invega 1.5mg Extended-Release Tablet

Convulsions Incidence:
<0.2%*
Severity: SEVERE
Onset: DELAYED
Irregular Periods Incidence:
<6.0%*
Severity: MILD
Onset: DELAYED
Increased Blood Fats Incidence:
<11.0%*
Severity: MODERATE
Onset: DELAYED
Increased Blood Sugar Incidence:
<11.0%*
Severity: MODERATE
Onset: DELAYED
Bundle-branch Block Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Stomach Pain Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Dry Mouth Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Nightmares Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Tiredness Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Gynecomastia Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Galactorrhea Incidence:
<4.0%*
Severity: MODERATE
Onset: DELAYED
Dystonic Reaction Incidence:
<14.0%*
Severity: MODERATE
Onset: DELAYED
Blurred Vision Incidence:
<3.0%*
Severity: MODERATE
Onset: EARLY
Weakness Incidence:
<4.0%*
Severity: MILD
Onset: DELAYED
Pseudoparkinsonism Incidence:
<14.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
<11.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Bladder Infection Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Rapid Heart Rate Incidence:
<14.0%*
Severity: MODERATE
Onset: RAPID
Heart Block Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
<9.0%*
Severity: MILD
Onset: DELAYED
No Menstrual Periods Incidence:
<6.0%*
Severity: MILD
Onset: DELAYED
Postural Low Blood Pressure Incidence:
<4.0%*
Severity: MODERATE
Onset: DELAYED
Sore Throat Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Shaking Incidence:
<12.0%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
<2.0%*
Severity: MODERATE
Onset: EARLY
Extra Saliva Production Incidence:
<6.0%*
Severity: MILD
Onset: EARLY
High Cholesterol Incidence:
<11.0%*
Severity: MODERATE
Onset: DELAYED
Fainting Incidence:
0.8%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Tooth Pain Incidence:
1.0-3.0%*
Severity: MILD
Onset: DELAYED
Dyskinesia Incidence:
1.0-9.0%*
Severity: MODERATE
Onset: DELAYED
Dysarthria Incidence:
1.0-4.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
1.0-6.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Drowsiness Incidence:
1.0-26.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
1.0-3.0%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
1.0-3.0%*
Severity: MILD
Onset: EARLY
High Triglycerides Incidence:
1.3-13.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
2.0-8.0%*
Severity: MILD
Onset: EARLY
Causing To Be Hungry Incidence:
2.0-3.0%*
Severity: MILD
Onset: DELAYED
Hyperkinesis Incidence:
3.0-17.0%*
Severity: MILD
Onset: DELAYED
Restlessness Incidence:
3.0-17.0%*
Severity: MODERATE
Onset: DELAYED
Weight Gain Incidence:
3.0-19.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
4.0-15.0%*
Severity: MILD
Onset: EARLY
Constipation Incidence:
4.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Distressed Incidence:
4.0-10.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
5.0-6.0%*
Severity: MILD
Onset: EARLY
High Prolactin Level Incidence:
>10.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Invega 1.5mg Extended-Release Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Alcohol and Invega 1.5mg Extended-Release Tablet(Paliperidone)
Alcohol and CNS Depressants(Paliperidone)
Avoid alcohol-containing drinks while taking this medicine. Using this drug along with alcohol can lead to serious side effects. You may feel drowsy or more tired when taking these drugs together. Do not drive or operate machinery until you know how this drug affects you, and especially if you are drinking alcohol-containing beverages. If you notice slurred speech, confusion, severe weakness, or difficulty breathing, contact your health care provider immediately.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Invega

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5